An update on heparin-induced thrombocytopenia: diagnosis and management

References

• Greinacher A, CLINICAL PRACTICE. Heparin-induced thrombocytopenia. N Engl J Med. 2015 Jul 16;373(3):252–261.
   PubMed Web of Science ®Google Scholar
• Greinacher A. Heparin-induced thrombocytopenia: frequency and pathogenesis. Pathophysiol Haemost Thromb. 2006;35(1–2):37–45.
   PubMedGoogle Scholar
• Alsaleh KA, Al-Nasser SM, Bates SM, et al. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol. 2008 Nov;83(11):876–878.
   PubMed Web of Science ®Google Scholar
• Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992 Jul 6;68(1):95–96.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994 Feb;71(2):247–251.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Michels I, Kiefel V, et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991 Dec 2;66(6):734–736.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003 Nov 10;163(20):2518–2524.
   PubMed Web of Science ®Google Scholar
• Alatri A, Armstrong AE, Greinacher A, et al. Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring rntithrombotic therapy - an European perspective. Thromb Res. 2012;129(4):426–433. doi:10.1016/j.thromres.2011.11.041.
   PubMed Web of Science ®Google Scholar
• Bakchoul T, Greinacher A. Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia. Ther Adv Hematol. 2012;3(4):237–251.
   PubMedGoogle Scholar
• Warkentin TE, Hayward CP, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994 Dec 1;84(11):3691–3699.
   PubMed Web of Science ®Google Scholar
• Hughes M, Hayward CP, Warkentin TE, et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood. 2000 Jul 1;96(1):188–194.
   PubMed Web of Science ®Google Scholar
• Mullier F, Minet V, Bailly N, et al. Platelet microparticle generation assay: a valuable test for immune heparin-induced thrombocytopenia diagnosis. Thromb Res. 2014 Jun;133(6):1068–1073.
   PubMed Web of Science ®Google Scholar
• Kasthuri RS, Glover SL, Jonas W, et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood. 2012 May 31;119(22):5285–5293.
   PubMed Web of Science ®Google Scholar
• Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood. 2001 Aug 15;98(4):1252–1254.
   PubMed Web of Science ®Google Scholar
• Rauova L, Hirsch JD, Greene TK, et al. Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood. 2010;116(23):5021–5031.
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003 May;121(4):535–555.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, et al., American College of Chest P. Treatment and prevention of heparin-induced thrombocytopenia: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008 Jun; 133(6_suppl):340S–80S.
   Google Scholar
• Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005 Jul;94(1):132–135.
   PubMed Web of Science ®Google Scholar
• Baroletti S, Hurwitz S, Conti NA, et al. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med. 2012 Jan;125(1):44–49.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995 May 18;332(20):1330–1335.
   PubMed Web of Science ®Google Scholar
• Hong AP, Cook DJ, Sigouin CS, et al. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 2003 Apr 15;101(8):3049–3051.
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Ischemic limb gangrene with pulses. N Engl J Med. 2015 Dec 10;373(24):2386–2388.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997 Nov 1;127(9):804–812.
   PubMed Web of Science ®Google Scholar
• Schindewolf M, Schwaner S, Wolter M, et al. Incidence and causes of heparin-induced skin lesions. CMAJ. 2009 Oct 13;181(8):477–481.
   PubMed Web of Science ®Google Scholar
• Rosenberger LH, Smith PW, Sawyer RG. Heparin-induced thrombocytopenia: an increasingly common cause of bilateral adrenal hemorrhage. J Am Geriatr Soc. 2011 Jun;59(6):1157–1158. author reply 8.
   PubMed Web of Science ®Google Scholar
• Lubenow N, Warkentin TE, Greinacher A, et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res. 2006;117(5):507–515.
   PubMed Web of Science ®Google Scholar
• Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost: JTH. 2006 Apr;4(4):759–765.
   PubMed Web of Science ®Google Scholar
• Nagler M, Fabbro T, Wuillemin WA. Prospective evaluation of the interobserver reliability of the 4Ts score in patients with suspected heparin-induced thrombocytopenia. J Thromb Haemost: JTH. 2012 Jan;10(1):151–152.
   PubMed Web of Science ®Google Scholar
• Cuker A, Gimotty PA, Crowther MA, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012 Nov 15;120(20):4160–4167.
   PubMed Web of Science ®Google Scholar
• Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost: JTH. 2010 Dec;8(12):2642–2650.
   PubMed Web of Science ®Google Scholar
• Messmore HL, Fabbrini N, Bird ML, et al. Simple scoring system for early management of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2011 Apr;17(2):197–201.
   PubMed Web of Science ®Google Scholar
• Lillo-LeLouët A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost: JTH. 2004 Nov;2(11):1882–1888.
   PubMed Web of Science ®Google Scholar
• Piednoir P, Allou N, Provenchère S, et al. Heparin-induced thrombocytopenia after cardiac surgery: an observational study of 1,722 patients. J Cardiothorac Vasc Anesth. 2012 Aug;26(4):585–590.
   PubMed Web of Science ®Google Scholar
• Bakchoul T, Zöllner H, Greinacher A. Current insights into the laboratory diagnosis of HIT. Int J Lab Hematol. 2014 Jun;36(3):296–305.
   PubMed Web of Science ®Google Scholar
• Morel-Kopp M-C, Aboud M, Tan CW, et al. Whole blood impedance aggregometry detects heparin-induced thrombocytopenia antibodies. Thromb Res. 2010 May;125(5):e234–9.
   Google Scholar
• Morel-Kopp M-C, Tan CW, Brighton TA, et al. Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thromb Haemost. 2012 Mar;107(3):575–583.
   PubMed Web of Science ®Google Scholar
• Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993 Apr 1;69(4):344–350.
   PubMed Web of Science ®Google Scholar
• Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986 Jan;67(1):27–30.
   PubMed Web of Science ®Google Scholar
• Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1995 Dec;104(6):648–654.
   PubMed Web of Science ®Google Scholar
• Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994 Jan;93(1):81–88.
   PubMed Web of Science ®Google Scholar
• Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99(19):2530–2536.
   PubMed Web of Science ®Google Scholar
• Regnault V, De Maistre E, Carteaux J-P, et al. Platelet activation induced by human antibodies to interleukin-8. Blood. 2003 Feb 15;101(4):1419–1421.
   PubMed Web of Science ®Google Scholar
• Bounameaux C, Boehlen F, Membré A, et al. Heparin-induced thrombocytopenia associated with interleukin-8-dependent platelet activation in a patient with antiphospholipid syndrome. Eur J Haematol. 2007 Dec;79(6):550–553.
   PubMed Web of Science ®Google Scholar
• Althaus K, Strobel U, Warkentin TE, et al. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res. 2011 Sep;128(3):256–260.
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Gerdsen F, Ackermann H, et al. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2001 Jun;113(4):886–890.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JA, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med. 2005 Dec;146(6):341–346.
   PubMed Web of Science ®Google Scholar
• Bakchoul T, Giptner A, Najaoui A, et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost: JTH. 2009 Aug;7(8):1260–1265.
   PubMed Web of Science ®Google Scholar
• Nagler M, Bachmann LM, Ten Cate H, et al. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2016;127(5):546–557. doi:10.1182/blood-2015-07-661215.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JI, Moore JC, et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost: JTH. 2008 Aug;6(8):1304–1312.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Ittermann T, Bagemühl J, et al. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost: JTH. 2010 Sep;8(9):2025–2031.
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Uhl L, Huang W-Y, et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost: JTH. 2004 Dec;2(12):2133–2137.
   PubMed Web of Science ®Google Scholar
• Selleng S, Schreier N, Wollert H-G, et al. The diagnostic value of the anti-PF4/heparin immunoassay high-dose heparin confirmatory test in cardiac surgery patients. Anesth Analg. 2011;112(4):774–776.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JI. No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. J Thromb Haemost: JTH. 2006 Jan;4(1):281–282.
   PubMed Web of Science ®Google Scholar
• Whitlatch NL, Kong DF, Metjian AD, et al. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood. 2010 Sep 9;116(10):1761–1766.
   PubMed Web of Science ®Google Scholar
• Bakchoul T, Giptner A, Bein G, et al. Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res. 2011 Apr;127(4):345–348.
   PubMed Web of Science ®Google Scholar
• Meyer O, Salama A, Pittet N, et al. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet. 1999 Oct 30;354(9189):1525–1526.
   PubMed Web of Science ®Google Scholar
• Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost: JTH. 2007 Jul;5(7):1373–1379.
   PubMed Web of Science ®Google Scholar
• Linkins LA, Bates SM, Lee AY, et al. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood. 2015 Jul 30;126(5):597–603.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JI, Raschke R, et al. Performance characteristics of a rapid assay for anti-PF4/heparin antibodies: the particle immunofiltration assay. J Thromb Haemost. 2007 Aug 3;5:2308–2310.
   PubMed Web of Science ®Google Scholar
• Sachs UJ, Von Hesberg UJ, Santoso S, et al. Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). Thromb Haemost. 2011 Nov 30;106(6):1197–1202.
   PubMed Web of Science ®Google Scholar
• Legnani C, Cini M, Pili C, et al. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost. 2010;104(2):402–409.
   PubMed Web of Science ®Google Scholar
• Althaus K, Hron G, Strobel U, et al. Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thromb Res. 2013;131(3):e85–90.
   PubMed Web of Science ®Google Scholar
• Sun L, Gimotty PA, Lakshmanan S, et al. Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. A systematic review and meta-analysis. Thromb Haemost. 2016 Jan 14;115(5). [Epub ahead of print].
   PubMedGoogle Scholar
• Chong BH, Ismail F, Cade J, et al. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood. 1989 May 1;73(6):1592–1596.
   PubMed Web of Science ®Google Scholar
• Krauel K, Fürll B, Warkentin TE, et al. Heparin-induced thrombocytopenia–therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost: JTH. 2008 Dec;6(12):2160–2167.
   PubMed Web of Science ®Google Scholar
• Goldfarb MJ, Blostein MD. Fondaparinux in acute heparin-induced thrombocytopenia: a case series. J Thromb Haemost: JTH. 2011 Dec;9(12):2501–2503.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Davidson BL, Büller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest. 2011 Aug;140(2):366–373.
   PubMed Web of Science ®Google Scholar
• Kang M, Alahmadi M, Sawh S, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015 Feb 5;125(6):924–929.
   PubMed Web of Science ®Google Scholar
• Baron SJ, Yeh RW, Cruz-Gonzalez I, et al. Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease. Catheter Cardiovasc Interv: Official J Soc Cardiac Angiography Interv. 2008 Jul 1;72(1):116–120.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost. 2008 May;99(5):830–839.
   PubMed Web of Science ®Google Scholar
• Levy JH, Spyropoulos AC, Samama CM, et al. Direct oral anticoagulants: new drugs and new concepts. JACC Cardiovasc Interv. 2014 Dec;7(12):1333–1351.
   PubMed Web of Science ®Google Scholar
• Krauel K, Hackbarth C, Fürll B, et al. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood. 2012 Feb 2;119(5):1248–1255.
   PubMed Web of Science ®Google Scholar
• Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin Thromb Hemost. 2012 Feb;38(1):31–37.
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Piechottka GP, Rabe F, et al. Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res. 2000;100(1):55–60.
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Expert Opin Drug Saf. 2014 Jan;13(1):25–43.
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Should vitamin K be administered when HIT is diagnosed after administration of coumarin? J Thromb Haemost: JTH. 2006 Apr;4(4):894–896.
   PubMed Web of Science ®Google Scholar
• Salmela B, Joutsi-Korhonen L, Saarela E, et al. Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant. Thromb Res. 2010;125(6):538–544.
   PubMed Web of Science ®Google Scholar
• Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion. 2008 Oct;48(10):2128–2132.
   PubMed Web of Science ®Google Scholar
• Refaai MA, Chuang C, Menegus M, et al. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost: JTH. 2010 Jun;8(6):1419–1421.
   PubMed Web of Science ®Google Scholar
• Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015 Feb 26;125(9):1470–1476.
   PubMed Web of Science ®Google Scholar
• Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004 Jan 12;164(1):66–70.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Cook RJ, Sarode R, et al. Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. Blood. 2015 Jul 23;126(4):486–493.
   PubMed Web of Science ®Google Scholar
• Linkins L-A, Dans AL, Moores LK, et al., American College of Chest P. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb; 141(2):e495S–530S.
   Google Scholar
• Greinacher A, Kohlmann T, Strobel U, et al. The temporal profile of the anti-PF4/heparin immune response. Blood. 2009 May 14;113(20):4970–4976.
   PubMed Web of Science ®Google Scholar
• Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost: JTH. 2010 Jan;8(1):30–36.
   PubMed Web of Science ®Google Scholar
• Selleng K, Schütt A, Selleng S, et al. Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion. 2010 Jan;50(1):32–39.
   PubMed Web of Science ®Google Scholar
• Selleng S, Haneya A, Hirt S, et al. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood. 2008 Nov 15;112(10):4024–4027.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Dasgupta I. National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol, Dial, Transplant: Official Publn Eur Dial Transpl Assoc Eur Ren Assoc. 2007 Jun;22(6):1680–1684.
   PubMed Web of Science ®Google Scholar
• Carrier M, Knoll GA, Kovacs MJ, et al. The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thromb Res. 2007;120(2):215–220.
   PubMed Web of Science ®Google Scholar
• Tholl U, Greinacher A, Overdick K, et al. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol, Dial, Transplant: Official Publn Eur Dial Transpl Assoc Eur Ren Assoc. 1997 Dec;12(12):2750–2755.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Kusano H, Wanaka K, et al. Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb/Hemost: Official J Int Acad Clin Appl Thromb/Hemost. 2007 Apr;13(2):182–187.
   PubMed Web of Science ®Google Scholar
• Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005 Oct 15;106(8):2710–2715.
   PubMed Web of Science ®Google Scholar
• Greinacher A, Gopinadhan M, Günther J-U, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2386–2393.
   PubMed Web of Science ®Google Scholar
• Group PIftCCCT, the A, New Zealand Intensive Care Society Clinical Trials G, Cook D, Meade M, Guyatt G, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011 Apr 7;364(14):1305–1314.
   PubMed Web of Science ®Google Scholar
• Douketis J, Cook D, Meade M, et al., Canadian Critical Care Trials G. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med. 2008 Sep 8;168(16):1805–1812.
   PubMedGoogle Scholar